Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 341

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 341
---
 $
        29,895

        Variable lease cost

        68,624

        38,442

        Total lease cost
         
        $
        103,644

        $
        68,337

        Other information

        Operating lease payments
         
        $
        33,225

        $
        21,608

        Operating lease liabilities arising from obtaining ROU assets
         
        $
        35,361

        $
        80,203

        Weighted-average remaining lease term
         
        11.7 years

        11.2 years

        Weighted-average discount rate

        8.0
        %

        9.1
        %

F-37

 The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of December 31, 2024: 

        For the Year Ended December 31, 2024

        (in thousands)

        2025
         
        $
        31,758

        2026

        31,530

        2027

        31,556

        2028

        32,279

        2029

        25,796

        Thereafter

        229,353

        Total minimum lease payments

        382,272

        Less: imputed interest and tenant incentive reimbursable by lessors

        (176,526
        )

        Total operating lease liabilities
         
        $
        205,746

        Included in the consolidated balance sheet:

        Current portion of lease liabilities within other current liabilities
         
        $
        13,273

        Lease liabilities, non-current

        192,473

        Total operating lease liabilities
         
        $
        205,746

20. EARNINGS (LOSS) PER SHAREBasic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the treasury stock method for stock awards and the if-converted method for convertible debt by dividing net income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding. Given that the Company recorded a net loss for the years ended December 31, 2023 and 2022, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be